We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Broadly Neutralizing Antibodies Protect Mice from Alphavirus Infection

By LabMedica International staff writers
Posted on 24 Nov 2015
Print article
Image: Cryoelectron micrograph reconstruction of the Chikungunya virus (Photo courtesy of the Washington University School of Medicine).
Image: Cryoelectron micrograph reconstruction of the Chikungunya virus (Photo courtesy of the Washington University School of Medicine).
While screening a panel of mouse and human monoclonal antibodies (MAbs) that had been raised against Chikungunya virus, researchers identified several with inhibitory activity against multiple other arthritogenic alphaviruses.

The arthritogenic alphaviruses, which include Chikungunya virus, Mayaro virus, and O’nyong-nyong virus among others, characteristically cause symptoms of fever followed by arthritis-like joint pain. Currently there is no vaccine or treatment for chikungunya or the other alphaviruses.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) screened 60 neutralizing mouse and human anti-chikungunya monoclonal antibodies and determined that 10 also recognized three or more different arthritogenic alphaviruses. Passive transfer of these "broadly neutralizing" MAbs protected mice against infection by chikungunya, Mayaro, and O’nyong’nyong alphaviruses.

The investigators reported in the November 6, 2015, online edition of the journal Cell that the broadly neutralizing MAbs blocked multiple steps in the viral lifecycle, including entry into host cells and egress. The antibodies were shown to bind to a conserved epitope on the B domain of the viral E2 glycoprotein. The cryoelectron microscopy structure of a Fab fragment bound to the chikungunya E2 B domain determined at 1.6 nanometer resolution showed that antibody binding caused the repositioning of the A domain of E2 so that it was able to cross-link neighboring spikes. This change in the three-dimensional structure of the proteins on the surface of the virus explained how the antibodies were able to prevent viral infection.

“There is a lot of emphasis on identifying and understanding broadly neutralizing antibodies for other viruses - HIV, Hepatitis C virus, Dengue virus, influenza virus - but most of those antibodies neutralize different strains of the same virus,” said senior author Dr. Michael Diamond, professor of medicine at the Washington University School of Medicine. “What we have identified here are antibodies that actually neutralize several different alphaviruses.”

“We have more work to do but are encouraged that targeting this epitope could be a viable strategy for developing vaccines or treatments against chikungunya and other related viruses that cause significant disease worldwide,” said Dr. Diamond. “If you can make an antibody response against this region, you may be able to protect against many viruses in the family. Our group is making proteins now that focus on this epitope, and we are planning to start immunizing animals soon to see if we generate the right kinds of antibodies.”

Related Links:

Washington University School of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.